2025 Q3 -tulosraportti
47 päivää sitten1,73 USD/osake
Irtoamispäivä 13.2.2026
0,56 %Tuotto/v
Tarjoustasot
Määrä
Osto
10
Myynti
Määrä
101
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 11.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 30.10. | |
| 2025 Q2 -tulosraportti | 7.8. | |
| Vuosittainen yhtiökokous 2025 | 5.5. | |
| 2025 Q1 -tulosraportti | 1.5. | |
| 2024 Q4 -tulosraportti | 6.2. |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·16 t sitten · MuokattuMarket value of Eli Lilly approx 6 times larger than Novo Nordisk completely incomprehensible to me. Even with all the USA bias and USA first and the orange monkey, Novo cannot be kept down in the long run, the truth will also emerge in the USA. Novo has the best obesity products with the fewest side effects. I believe more and more patients will opt out of Lilly products going forward due to greater side effects and opt for Novo products which are not quite as effective but with fewer side effects and gentler on the body. We'll see if I'm right. Future financial reports in the coming quarters will show this. Lilly has captured market shares from Novo in '25 admittedly, but I believe that pattern will change already in '26. We'll see.
·7 t sitten · MuokattuI think you're onto something. LLY has gained market share over the past year, but as you say, fewer people probably have the tolerance to handle their side effects. As a doctor, one would then say, maybe we should try something else? And something else would often be a Novo product with a milder profile. LLY's focus has probably been to beat Novo on maximum weight reduction in the shortest possible time. But unfortunately, that's probably a failed strategy in the long run. Big headlines about %-wise weight reduction over x number of weeks create expectations, but over time, doctors will ultimately choose what is the best approach for a balanced weight reduction. Therefore, I believe we will see a shift towards a more balanced weight reduction, which is the key to lasting success, and an equalization of market value between these two companies - with new competitors entering in the long term.- ·3 päivää sitten · MuokattuAgain today we see huge trading volume in Eli Lilly in USA approx 5 times larger than Novo. Is there anyone who can explain this difference between 2 companies approximately similar in size and product offering?? Will that relationship between the 2 companies ever change??
·2 päivää sitten · MuokattuThere will always be a higher turnover in a company that has a much larger market value. Eli Lilly is after all worth around 6 trillion DKK, or valued over 4 times higher than Novo. The trades are thus also worth more, and provide a higher revenue value. Besides that, there will generally also be a higher proportional turnover in optimistic stocks. Eli Lilly's growth is expected to generate higher earnings, due to their larger market share and easier-to-use (here I'm primarily thinking of Zepbound, which doesn't need to be taken as often as Wegovy or Ozempic) products, compared to Novo. The latest data from Retatrutid shows 23% weight loss in 68 weeks (here there is great short-term optimism, which further increases turnover). Better than Novo's 7.2 mg Wegovy medicine, with 20.7 percent in 72 weeks, which has otherwise received positive reviews from the EU. There is a fundamental pessimism about Novo, because they have faced very strong competition in recent years, and today have significant headwinds with a very biased American government, which clearly prefers American companies, like LLY. - ·3 päivää sittenhttps://medwatch.com/News/Pharma___Biotech/article18839298.ece always good with unfair competitive conditions and corruption in the USA.
10.12.10.12.Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama https://investor.lilly.com/news-releases/news-release-details/lilly-build-6-billion-facility-manufacture-active-pharmaceutical
·7.12.Found an interesting article about how much revenue is required to justify Eli Lilly's valuation. https://www.patreon.com/posts/145222738?utm_campaign=postshare_creator
·10.12.Eli Lilly trades at a significantly higher P/E than Novo Nordisk, because the market prices in higher growth expectations, a broader pipeline (incl. Alzheimer’s), and strong momentum in the obesity/diabetes segment. Novo Nordisk has a more focused profile and therefore trades at lower multiples, even though the company is very profitable. Source: Copilot
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
47 päivää sitten1,73 USD/osake
Irtoamispäivä 13.2.2026
0,56 %Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·16 t sitten · MuokattuMarket value of Eli Lilly approx 6 times larger than Novo Nordisk completely incomprehensible to me. Even with all the USA bias and USA first and the orange monkey, Novo cannot be kept down in the long run, the truth will also emerge in the USA. Novo has the best obesity products with the fewest side effects. I believe more and more patients will opt out of Lilly products going forward due to greater side effects and opt for Novo products which are not quite as effective but with fewer side effects and gentler on the body. We'll see if I'm right. Future financial reports in the coming quarters will show this. Lilly has captured market shares from Novo in '25 admittedly, but I believe that pattern will change already in '26. We'll see.·7 t sitten · MuokattuI think you're onto something. LLY has gained market share over the past year, but as you say, fewer people probably have the tolerance to handle their side effects. As a doctor, one would then say, maybe we should try something else? And something else would often be a Novo product with a milder profile. LLY's focus has probably been to beat Novo on maximum weight reduction in the shortest possible time. But unfortunately, that's probably a failed strategy in the long run. Big headlines about %-wise weight reduction over x number of weeks create expectations, but over time, doctors will ultimately choose what is the best approach for a balanced weight reduction. Therefore, I believe we will see a shift towards a more balanced weight reduction, which is the key to lasting success, and an equalization of market value between these two companies - with new competitors entering in the long term.
- ·3 päivää sitten · MuokattuAgain today we see huge trading volume in Eli Lilly in USA approx 5 times larger than Novo. Is there anyone who can explain this difference between 2 companies approximately similar in size and product offering?? Will that relationship between the 2 companies ever change??·2 päivää sitten · MuokattuThere will always be a higher turnover in a company that has a much larger market value. Eli Lilly is after all worth around 6 trillion DKK, or valued over 4 times higher than Novo. The trades are thus also worth more, and provide a higher revenue value. Besides that, there will generally also be a higher proportional turnover in optimistic stocks. Eli Lilly's growth is expected to generate higher earnings, due to their larger market share and easier-to-use (here I'm primarily thinking of Zepbound, which doesn't need to be taken as often as Wegovy or Ozempic) products, compared to Novo. The latest data from Retatrutid shows 23% weight loss in 68 weeks (here there is great short-term optimism, which further increases turnover). Better than Novo's 7.2 mg Wegovy medicine, with 20.7 percent in 72 weeks, which has otherwise received positive reviews from the EU. There is a fundamental pessimism about Novo, because they have faced very strong competition in recent years, and today have significant headwinds with a very biased American government, which clearly prefers American companies, like LLY.
- ·3 päivää sittenhttps://medwatch.com/News/Pharma___Biotech/article18839298.ece always good with unfair competitive conditions and corruption in the USA.
- 10.12.10.12.Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama https://investor.lilly.com/news-releases/news-release-details/lilly-build-6-billion-facility-manufacture-active-pharmaceutical
- ·7.12.Found an interesting article about how much revenue is required to justify Eli Lilly's valuation. https://www.patreon.com/posts/145222738?utm_campaign=postshare_creator·10.12.Eli Lilly trades at a significantly higher P/E than Novo Nordisk, because the market prices in higher growth expectations, a broader pipeline (incl. Alzheimer’s), and strong momentum in the obesity/diabetes segment. Novo Nordisk has a more focused profile and therefore trades at lower multiples, even though the company is very profitable. Source: Copilot
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
10
Myynti
Määrä
101
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 11.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 30.10. | |
| 2025 Q2 -tulosraportti | 7.8. | |
| Vuosittainen yhtiökokous 2025 | 5.5. | |
| 2025 Q1 -tulosraportti | 1.5. | |
| 2024 Q4 -tulosraportti | 6.2. |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
47 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 11.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 30.10. | |
| 2025 Q2 -tulosraportti | 7.8. | |
| Vuosittainen yhtiökokous 2025 | 5.5. | |
| 2025 Q1 -tulosraportti | 1.5. | |
| 2024 Q4 -tulosraportti | 6.2. |
Datan lähde: FactSet, Quartr
1,73 USD/osake
Irtoamispäivä 13.2.2026
0,56 %Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·16 t sitten · MuokattuMarket value of Eli Lilly approx 6 times larger than Novo Nordisk completely incomprehensible to me. Even with all the USA bias and USA first and the orange monkey, Novo cannot be kept down in the long run, the truth will also emerge in the USA. Novo has the best obesity products with the fewest side effects. I believe more and more patients will opt out of Lilly products going forward due to greater side effects and opt for Novo products which are not quite as effective but with fewer side effects and gentler on the body. We'll see if I'm right. Future financial reports in the coming quarters will show this. Lilly has captured market shares from Novo in '25 admittedly, but I believe that pattern will change already in '26. We'll see.·7 t sitten · MuokattuI think you're onto something. LLY has gained market share over the past year, but as you say, fewer people probably have the tolerance to handle their side effects. As a doctor, one would then say, maybe we should try something else? And something else would often be a Novo product with a milder profile. LLY's focus has probably been to beat Novo on maximum weight reduction in the shortest possible time. But unfortunately, that's probably a failed strategy in the long run. Big headlines about %-wise weight reduction over x number of weeks create expectations, but over time, doctors will ultimately choose what is the best approach for a balanced weight reduction. Therefore, I believe we will see a shift towards a more balanced weight reduction, which is the key to lasting success, and an equalization of market value between these two companies - with new competitors entering in the long term.
- ·3 päivää sitten · MuokattuAgain today we see huge trading volume in Eli Lilly in USA approx 5 times larger than Novo. Is there anyone who can explain this difference between 2 companies approximately similar in size and product offering?? Will that relationship between the 2 companies ever change??·2 päivää sitten · MuokattuThere will always be a higher turnover in a company that has a much larger market value. Eli Lilly is after all worth around 6 trillion DKK, or valued over 4 times higher than Novo. The trades are thus also worth more, and provide a higher revenue value. Besides that, there will generally also be a higher proportional turnover in optimistic stocks. Eli Lilly's growth is expected to generate higher earnings, due to their larger market share and easier-to-use (here I'm primarily thinking of Zepbound, which doesn't need to be taken as often as Wegovy or Ozempic) products, compared to Novo. The latest data from Retatrutid shows 23% weight loss in 68 weeks (here there is great short-term optimism, which further increases turnover). Better than Novo's 7.2 mg Wegovy medicine, with 20.7 percent in 72 weeks, which has otherwise received positive reviews from the EU. There is a fundamental pessimism about Novo, because they have faced very strong competition in recent years, and today have significant headwinds with a very biased American government, which clearly prefers American companies, like LLY.
- ·3 päivää sittenhttps://medwatch.com/News/Pharma___Biotech/article18839298.ece always good with unfair competitive conditions and corruption in the USA.
- 10.12.10.12.Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama https://investor.lilly.com/news-releases/news-release-details/lilly-build-6-billion-facility-manufacture-active-pharmaceutical
- ·7.12.Found an interesting article about how much revenue is required to justify Eli Lilly's valuation. https://www.patreon.com/posts/145222738?utm_campaign=postshare_creator·10.12.Eli Lilly trades at a significantly higher P/E than Novo Nordisk, because the market prices in higher growth expectations, a broader pipeline (incl. Alzheimer’s), and strong momentum in the obesity/diabetes segment. Novo Nordisk has a more focused profile and therefore trades at lower multiples, even though the company is very profitable. Source: Copilot
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
10
Myynti
Määrä
101
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt